February 14th 2025
Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.
Strategies for Integrating Biologic Therapy Into the Management of Eosinophilic Esophagitis
1.5 Credits / Immunology, Gastroenterology
View More
Navigating Next-Generation Therapies for the Management of Acid-Related Disorders
1.5 Credits / Gastroenterology
View More
Biologic Therapy for the Management of Eosinophilic Esophagitis in Children: The Evolving Treatment Paradigm
1.5 Credits / Gastroenterology, Immunology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Foundations in the Management of Eosinophilic Esophagitis: Pathophysiology, Clinical, Economic, and Quality of...
1.0 Credit / Gastroenterology, Immunology
View More
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
The Evolving Treatment Paradigm for the Management of Eosinophilic Esophagitis and the Future of Oral Therapie...
1.0 Credit / Gastroenterology, Immunology
View More
The Role of the Community Pharmacist in the Management of Eosinophilic Esophagitis
1.0 Credit / Gastroenterology, Immunology
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Optimizing Treatment Strategies: A Comprehensive Approach to Primary Biliary Cholangitis and Pruritus
1.5 Credits / Hematologic Cancer, Hematology, Oncology
View More
Guselkumab Shows Positive Results in Trials for Crohn’s Disease, Ulcerative Colitis
October 10th 2024Guselkumab is currently approved by the FDA to treat adults with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with moderately to severely active ulcerative colitis.
Tonix Pharmaceuticals Launches Campaign Promoting Non-Oral Medications for Gastroparesis, Migraine
September 9th 2024Whereby gastroparesis can hinder the absorption of oral medications in the stomach, Tonix Pharmaceuticals is promoting alternative migraine treatments that bypass the digestive system.